Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | GSK3A | P49840 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 6/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13962001 | 0.87 | BACE1 (0.49) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13962003 | 0.85 | BACE1 (0.47) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL2900738 | 0.84 | BACE1 (0.56) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13962002 | 0.83 | BACE1 (0.46) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13027444 | 0.83 | PIM1 (0.57) | GSK3BGSK3APIM1PIM3PIM2 | |
| SCHEMBL13028203 | 0.82 | BACE1 (0.51) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13028209 | 0.82 | BACE1 (0.50) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13028202 | 0.82 | IRAK4 (0.51) | BACE1PIM1PIM3PIM2MAPT | |
| SCHEMBL13028222 | 0.81 | GSK3B (0.52) | BACE1GSK3BGSK3APIM1PIM3 | |
| SCHEMBL13028207 | 0.81 | BACE1 (0.49) | BACE1GSK3BGSK3APIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742139-B2 | No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-03 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293747-B2 | Heterocyclic amide compounds as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | BACE1 550/4885GSK3B 192/4885GSK3A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.